- 11		}		
1				
2	Attorney General of California JAMES M. LEDAKIS			
3	Supervising Deputy Attorney General			
	Deputy Attorney General			
.4	110 West "A" Street, Suite 1100	·		
5	P.O. Box 85266			
6	San Diego, CA 92186-5266 Telephone: (619) 645-2143			
7	Facsimile: (619) 645-2061			
8	3			
9	BEFORE THE BOARD OF REGISTERED NURSING			
10	DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA			
11				
	Case No	2011-774		
12	in the Watter of the Accusation Against:			
. 13	1) 222222222222222222222222222222222222	JSATION		
14				
15	5 Registered Nurse License No. 530047			
16	6 Respondent.			
17	7			
18	8			
19	9 Complainant alleges:	·		
20				
21				
22		official capacity as the Executive Officer of the Board of Registered Nursing, Department of		
23		Consumer Affairs.		
. 24	24 2. On or about February 25, 1997, the Board of	2. On or about February 25, 1997, the Board of Registered Nursing issued Registered		
2,5	Nurse License Number 530047 to Kristy Jean Bennett (R	Nurse License Number 530047 to Kristy Jean Bennett (Respondent). The Registered Nurse		
26	License was in full force and effect at all times relevant to the charges brought herein and expired			
. 27	on September 30, 2010, and has not been renewed.			
28	28 ///			
	1	.		

JURISDICTION

- 3. This Accusation is brought before the Board of Registered Nursing (Board),
 Department of Consumer Affairs, under the authority of the following laws. All section
 references are to the Business and Professions Code unless otherwise indicated.
- 4. Section 2750 of the Business and Professions Code ("Code") provides, in pertinent part, that the Board may discipline any licensee, including a licensee holding a temporary or an inactive license, for any reason provided in Article 3 (commencing with section 2750) of the Nursing Practice Act.
- 5. Section 2764 of the Code provides, in pertinent part, that the expiration of a license shall not deprive the Board of jurisdiction to proceed with a disciplinary proceeding against the licensee or to render a decision imposing discipline on the license.
- 6. Section 2811(b) of the Code provides, in pertinent part, that the Board may renew an expired license at any time within eight years after the expiration.

STATUTORY PROVISIONS

7. Section 2761 of the Code states:

The board may take disciplinary action against a certified or licensed nurse or deny an application for a certificate or license for any of the following:

- (a) Unprofessional conduct, which includes, but is not limited to, the following:
 - (1) Incompetence, or gross negligence in carrying out usual certified or licensed nursing functions.

8. Section 2762 of the Code states:

In addition to other acts constituting unprofessional conduct within the meaning of this chapter [the Nursing Practice Act], it is unprofessional conduct for a person licensed under this chapter to do any of the following:

(a) Obtain or possess in violation of law, or prescribe, or except as directed by a licensed physician and surgeon, dentist, or podiatrist administer to himself or herself, or furnish or administer to another, any controlled substance as defined in Division 10 (commencing with Section 11000) of the Health and Safety Code or any dangerous drug or dangerous device as defined in Section 4022.

1	(e) Falsify, or make grossly incorrect, grossly inconsistent, or unintelligible entries in any hospital, patient, or other record pertaining to the substances described in subdivision (a) of this section."		
2			
3	REGULATORY PROVISIONS		
4	9. Title 16, California Code of Regulations, section 1442, provides:		
5	As used in Section 2761 of the code, "gross negligence" includes an extreme		
6	departure from the standard of care which, under similar circumstances, would have ordinarily been exercised by a competent registered nurse. Such an extreme		
7	departure means the repeated failure to provide nursing care as required or failure to provide care or to exercise ordinary precaution in a single situation which the nurse knew, or should have known, could have jeopardized the client's health or		
8			
9	life.		
10	COST RECOVERY		
11	10. Section 125.3 of the Code provides, in pertinent part, that the Board may request the		
12	administrative law judge to direct a licentiate found to have committed a violation or violations of		
13	the licensing act to pay a sum not to exceed the reasonable costs of the investigation and		
14	enforcement of the case.		
15	<u>DRUGS</u>		
16	11. Ambien, a brand name for zolpidem tartrate, is a Schedule IV controlled substance as	;	
17	designated by Health and Safety Code section 11057(d)(32), and is a dangerous drug pursuant to		
18	Business & Professions Code section 4022.		
19	12. Ativan, the brand name for lorazepam, is a Schedule IV controlled substance as		
20	designated by Health and Safety Code section 11057(d)(16), and is a dangerous drug pursuant to		
21	Business and Professions Code section 4022. Ativan is used in the treatment of anxiety disorders		
22	and for short-term (up to 4 months) relief of the symptoms of anxiety.		
23	13. Dilaudid, a brand name for hydromorphone, is a Schedule II controlled substance as		
24	designated by Health and Safety Code Section 11055(b)(1)(K) and is a dangerous drug pursuant		
25	to Business and Professions Code section 4022. Dilaudid is a narcotic analgesic prescribed for		
26	the relief of moderate to severe pain.		
27			
28			

///

///

///

///

- 14. Morphine, is a Schedule II controlled substance as designated by Health and Safety Code section 11055(b)(1)(M), and is a dangerous drug pursuant to Business and Professions Code section 4022.
- 15. Norco, a brand name for hydrocodone with acetaminophen, is a dangerous drug pursuant to section 4022, and a Schedule II controlled substance as designated by Health and Safety Code section 11055(b)(1)(J).
- 16. Percocet, a brand name for acetaminophen/hydrocodone, is Schedule II controlled substance as designated by Health and Safety Code section 11055(b)(1)(J), and is a dangerous drug pursuant to Business & Professions Code section 4022. Percocet is a combination of a narcotic and an analgesic/antipyretic used to treat moderate to moderately severe pain.
- 17. Xanax, a brand name for alprazolam, is a Schedule IV controlled substance as designated by Health and Safety Code section 11057(d)(1), and is a dangerous drug pursuant to Business and Professions Code section 4022. Alprazolam tablets are indicated for the management of anxiety disorder or the short-term relief of symptoms of anxiety.

FACTUAL ALLEGATIONS

18. Respondent was employed as a registered nurse at Sharp Memorial Hospital in San Diego, California from August 18, 2008 through December 9, 2009. On or about December 2, 2009, the Lead Charge RN at Sharp Memorial Hospital was informed by two of Respondent's patients that they had not received medication. The first patient informed the Lead Charge RN that she did not receive Morphine and that she could not take Morphine. The second patient informed the Lead Charge RN that he had not received any pain medication from Respondent and that he was not in pain. Thereafter, an internal audit and investigation ensued. The investigation revealed that between the dates of October 23, 2009 and December 2, 2009, the following discrepancies were attributed to Respondent:

a. On October 23, 2009 at 1714 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis¹ for this patient. Respondent charted administration of 1 tablet of Norco 5/325 mg on the patient's Medication Administration Record (MAR) at 1700 hours. However, Respondent failed to document administration or wastage for the remaining 1 tablet of Norco 5/325 mg. Therefore, 1 tablet of Norco 5/325 mg is unaccounted for.

b. On October 23, 2009 at 1834 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. Respondent charted administration of 1 tablet of Percocet 5/325 mg on the patient's MAR at 1821 hours. However, Respondent failed to document administration or wastage of the remaining 1 tablet of Percocet 5/325 mg. Therefore, 1 tablet of Percocet 5/325 mg is unaccounted for.

20. Patient B

a. On November 1, 2009 at 0749 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

b. On November 1, 2009 at 1421 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.

¹ Pyxis is a trade name for the automatic single-unit dose medication dispensing system that records information such as patient name, physician orders, date and time medication was withdrawn, and the name of the licensed individual who withdrew and administered the medication. Each user/operator is given a user identification code to operate the control panel. Sometimes only portions of the withdrawn narcotics are given to the patient. The portions not given to the patient are referred to as "wastage." This waste must be witnessed by another authorized user and is also recorded by the Pyxis machine.

c. On November 1, 2009 at 1422 hours, Respondent removed 1 tablet of Ambien 5 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Ambien 5 mg is unaccounted for.

21. Patient C

- a. On October 27, 2009 at 0751 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- b. On October 28, 2009 at 1315 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- c. On October 28, 2009 at 1914 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.

22. Patient D

a. On October 20, 2009 at 0838 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

- b. On October 20, 2009 at 1011 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.
- c. On October 20, 2009 at 1213 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- d. On October 20, 2009 at 1512 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.

23. Patient E

- a. On October 23, 2009 at 0900 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- b. On October 23, 2009 at 1354 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

.18

a. On October 23, 2009 at 0748 hours, Respondent removed 1 tablet of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Percocet 5/325 mg is unaccounted for.

b. On October 23, 2009 at 1214 hours, Respondent removed 2 tablets of Ambien 5 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Ambien 5 mg are unaccounted for.

c. On October 23, 2009 at 1337 hours, Respondent removed 1 tablet of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Percocet 5/325 mg is unaccounted for.

25. Patient G

a. On October 27, 2009 at 0929 hours, Respondent removed 2 tablets of Norco 10/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 10/325 mg are unaccounted for.

b. On October 27, 2009 at 1336 hours, Respondent removed 2 tablets of Norco 10/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 10/325 mg are unaccounted for.

- c. On October 28, 2009 at 0900 hours, Respondent removed 1 tablet of Xanax .25 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Xanax .25 is unaccounted for.
- d. On October 28, 2009 at 1225 hours, Respondent removed 2 tablets of Norco 10/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 10/325 mg are unaccounted for.

26. Patient H

a. On November 4, 2009 at 0749 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

27. Patient I

- a. On November 12, 2009 at 0802 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- b. On November 12, 2009 at 1136 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

c. On November 12, 2009 at 1517 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

28. Patient J

- a. On November 18, 2009 at 0743 hours, Respondent removed 2 tablets of Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.
- b. On November 18, 2009 at 0843 hours, Respondent removed 1 tablet of Ativan 1 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Ativan 1 mg is unaccounted for.
- c. On November 18, 2009 at 1013 hours, Respondent removed 1 tablet of Dilaudid 2 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Dilaudid 1 mg is unaccounted for.
- d. On November 18, 2009 at 1103 hours, Respondent removed 2 tablets of Norcot 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
 - c. On November 18, 2009 at 1155 hours, Respondent removed 2 tablets of

Percocet 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Percocet 5/325 mg are unaccounted for.

- f. On November 18, 2009 at 1401 hours, Respondent removed 1 tablet of Ativan 1 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Ativan 1 mg is unaccounted for.
- g. On November 18, 2009 at 1556 hours, Respondent removed 1 tablet of Dilaudid 2 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Dilaudid 2 mg is unaccounted for.

29. Patient K

- a. On November 14, 2009 at 1408 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- b. On November 15, 2009 at 0753 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- c. On November 15, 2009 at 1200 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of

...

wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.

- d. On November 15, 2009 at 1429 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- e. On November 15, 2009 at 1727 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.
- f. On November 15, 2009 at 1813 hours, Respondent removed 2 mg of Ativan (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 mg of Ativan (Inj) are unaccounted for.
- g. On November 15, 2009 at 1858 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

30. Patient L

a: On November 18, 2009 at 1155 hours, Respondent removed 2 mg Ativan (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 mg Ativan (Inj) are unaccounted for.

.13

- b. On November 18, 2009 at 1208 hours, Respondent removed 2 tablets of Xanax .25 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Xanax .25 are unaccounted for.
- c. On November 18, 2009 at 1400 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- d. On November 18, 2009 at 1401 hours, Respondent removed 2 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 mg of Morphine (Inj) are unaccounted for.
- e. On November 19, 2009 at 0856 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- f. On November 19, 2009 at 1034 hours, Respondent removed 2 tablets of Xanax .25 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Xanax .25 are unaccounted for.
- g. On November 19, 2009 at 1034 hours, Respondent removed 2 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of

wastage for the medication withdrawn by Respondent. Therefore, 2 mg of Morphine (Inj) are unaccounted for.

f. On November 19, 2009 at 1313 hours, Respondent removed 1 tablet of Ativan 2 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 tablet of Ativan 2 mg is unaccounted for.

31. Patient M

- a. On November 18, 2009 at 1234 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.
- b. On November 18, 2009 at 1905 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- c. On November 19, 2009 at 0823 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.
- d. On November 19, 2009 at 1035 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

e. On November 19, 2009 at 1211 hours, Respondent removed 1 mg of Dilaudid (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 mg of Dilaudid (Inj) is unaccounted for.

32. Patient N:

- a. On December 2, 2009 at 0759 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- b. On December 2, 2009 at 1211 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.
- c. On December 2, 2009 at 1648 hours, Respondent removed 2 tablets of Norco 5/325 mg from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 tablets of Norco 5/325 mg are unaccounted for.

33. Patient O:

a. On December 2, 2009 at 0932 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.

- b. On December 2, 2009 at 1107 hours, Respondent removed 1 mg of Dilaudid (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 mg of Dilaudid (Inj) is unaccounted for.
- c. On December 2, 2009 at 1124 hours, Respondent removed 4 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 4 mg of Morphine (Inj) are unaccounted for.
- d: On December 2, 2009 at 1404 hours, Respondent removed 1 mg of Dilaudid (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 1 mg of Dilaudid (Inj) is unaccounted for.
- e. On December 2, 2009 at 1507 hours, Respondent removed 2 mg of Ativan (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 mg of Ativan (Inj) are unaccounted for.
- f. On December 2, 2009 at 1855 hours, Respondent removed 2 mg of Morphine (Inj) from the Pyxis for this patient. There is no indication in the patient's MAR that the medication withdrawn by Respondent was administered to the patient. There is no record of wastage for the medication withdrawn by Respondent. Therefore, 2 mg of Morphine (Inj) are unaccounted for.
- 34. The Proactive Diversion Report reflected that between October 20, 2009 and November 19, 2009, Respondent withdrew medication five standard deviations above the mean as compared to her peers. Following the results of the internal investigation, Respondent was interviewed by the RN Manager of 6W Surgical PCU of Sharp Memorial Hospital. During the

11.

interview, Respondent denied taking the medication that she failed to account for even though she was not asked if she was taking the drugs. Respondent stated that she forgot to chart and her day was very busy. Respondent was terminated on or about December 9, 2009.

35. During Respondent's last month of employment she would fail to show up for work and take naps during her lunch break. Respondent was also observed by co-workers sleeping in empty patient rooms and in the break room. Respondent also informed her co-workers that she was not able to sleep due to migraines. At the time Respondent's employment was terminated, Respondent was on a final warning for attendance issues.

FIRST CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Obtain Controlled Substances Unlawfully)

36. Respondent is subject to disciplinary action for unprofessional conduct under section 2762(a) in that while employed as a registered nurse at Sharp Memorial Hospital, Respondent unlawfully obtained and possessed controlled substances, as is more particularly set forth in paragraphs 18 through 35 above, which are incorporated herein as though set forth in full.

SECOND CAUSE FOR DISCIPLINE

(Unprofessional Conduct-Falsify or Make Grossly Incorrect or Inconsistent Entries)

37. Respondent is subject to disciplinary action for unprofessional conduct under Code section 2762(e) for falsifying or making grossly incorrect, inconsistent and/or unintelligible entries in the hospital records of Sharp Memorial Hospital by withdrawing medication, charging the withdrawal to patients who did not receive the drugs or for whom Respondent did not document administration or wastage of the drug as is more particularly set forth in paragraphs 18 through 35 above, which are incorporated herein as though set forth in full.

THIRD CAUSE FOR DISCIPLINE

(Unprofessional Conduct - Gross Negligence)

38. Respondent is subject to disciplinary action for unprofessional conduct under section 2761(a)(1) of the Code in that during her employment at Sharp Memorial Hospital, Respondent was grossly negligent as evidenced by her repeated failure to provide nursing care as required, specifically as it related to her management of the administration of controlled substances to her

Accusation